## **CURRICULUM VITAE**

## **BARBARA A. SORG**

Chair, R.S. Dow Neurobiology Legacy Research Institute 1225 NE 2<sup>nd</sup> Avenue Portland, OR 97232 PH: 503-413-1934

bsorg@downeurobiology.org

# **Education:**

B.S.	1981	Ball State University, Muncie, Indiana (Biology)
Ph.D.	1987	University of Maryland, College Park, Maryland (Biochemistry)

# **Professional Experience:**

1981-1985	Research Assistant and Teaching Assistant: Department of Chemistry and Biochemistry, University of Maryland, College Park, MD
1985-1987	Research Assistant: Neuropsychiatric Institute, University of California at Los Angeles, Los Angeles, CA
1987-1988	Postdoctoral Fellow: Program in Genetics and Cell Biology, Washington State University (WSU), Pullman, WA
1988-1990	Research Associate: Department of Psychology, WSU, Pullman, WA
1990-1998	Research Assistant Professor: Department of Veterinary and Comparative Anatomy, Pharmacology and Physiology (VCAPP), WSU, Pullman, WA
1998-1999	Assistant Professor, Tenure-Track: Department of VCAPP, WSU, Pullman, WA
1999-2004	Associate Professor: Department of VCAPP, WSU, Pullman, WA
1999-2003	Interim Associate Director and Interim Director, WSU Alcohol and Drug Abuse Program, Pullman, WA
2003-2014	Director, WSU Alcohol and Drug Abuse Program, Pullman, WA
2004-2019	Professor, Department of VCAPP (currently Integrative Physiology and Neuroscience; IPN), WSU, Pullman, WA
2011-2019	Co-Director, WSU Translational Addiction Research Center (TARC)
2018-2019	Adjunct faculty, Legacy Research Institute, Portland, OR
2019-present	Chair, Dow Neurobiology, Legacy Research Institute, Portland, OR

2019-present Adjunct professor, IPN, WSU

2019-present Adjunct professor, Department of Behavioral Neuroscience and Department of Chemical Physiology and Biochemistry, Oregon Health & Science University, Portland, OR

# **Research Grants:**

## Funded- Extramural

<b>DATE</b>		AMOUNT (TOTAL DIRECT)
08/92-08/94	(PI) Molecular Mechanisms of Cocaine NIH NIDA (Grant RO3 DA 07827)	Sensitization.
06/93-06/98	(PI) Stress and Role of Prefrontal Corte NIH NIDA (Grant R29 DA 08212)	
01/95-01/96	(PI) Development of an Animal Model for Sensitivity. Wallace Genetic Found	
01/96-01/97	(PI) Role of Stress and the Amygdala in for Multiple Chemical Sensitivity. Foundation.	
09/98-08/01	(PI) Role of Stress in Animal Model for Intolerance NIH NIEHS (Grant R01 ES09135)	<i>Chemical</i> \$ 340,971
02/99-01/03	(PI) Cortical Regulation of Sensitization NIH NIDA (Grant R01 DA 11787)	
07/99-6/00	(PI) Effects of Repeated Formaldehyde (Environmental Sensitivities Research	
Conference Grant	(PI) Role of Neural Plasticity in Chemic NIH NIEHS (R13)	cal Intolerance \$ 10,000
Conference Grant	(PI) Role of Neural Plasticity in Chemica (for 2000) Wallace Research Found	
04/01-1/03	(PI) Supplemental to: Cortical Regulation for Christopher Sanchez, M.S. studin NIH NIDA Research supplement for Minorities	ent
10/01-9/03	(PI) Cocaine and Extracellular Matrix NIH NIDA (Grant R21 DA 14915)	\$ 200,000
08/02-07/07	(PI) Animal Model for Chemical Intolera NIH NIEHS (R01 ES 09135 renews	

08/06-07/08	(PI)	Cocaine, Electroconvulsive Seizure and Neural Plasticity NIH NIDA (R21 DA020125)	\$ 401,360 (direct + ICR)
09/07-08/12	(Co-	I—Heiko Jansen, WSU, PI)  Circadian modulation of drug-seeking behavior  NIH NIDA (1R01DA023202)	\$1,659,715 (direct + ICR)
08/11-09/13	(PI)	Matrix metalloproteinases and cocaine NIH NIDA (R21DA030647)	\$ 275,000
06/12-05/17	(PI)	Extracellular matrix, cocaine, and memory NIH NIDA (R01DA033404-01)	\$1,000,000
04/16-03/22-NCE	(PI)	(Co-PI Travis Brown, University Wyoming)  Perineuronal nets and cocaine-associated memories  NIH NIDA (R01 DA040965-01A1)	\$1,976,843
04/18-06/23	(Co-	I) (PI Jonathan Wisor, WSU Spokane) Sleep deprivation elevates, and sleep alleviates, oxidative brain	(direct + ICR) e stress in the
09/19-08/22-NCE	(PI)	NIH NINDS (R01 NS078498-05)  Identifying prefrontal cortex neural ensembles in cocaine	\$1,883,160 (direct + ICR) -associated
		memories NIH R21 (DA047121) Cutting Edge Basic Research Awa (CEBRA) (direct + ICR)	
03/23-02/27	(PI)	Cocaine, parvalbumin, and perineuronal nets NIH R01 (DA55645) (6 <sup>th</sup> percentile ranking) (direct + ICR)	\$3,562,010
NIH grants: Sponsor or Co-sponsor			
07/07-06/08	(Men	tor) (Pre-doctoral Fellowship for Travis E. Brown)  Role of Matrix Metalloproteinases in Drug Relapse  NIH NRSA (F31 DA023729)	\$ 25,300
07/10-06/13	(Co-N	Mentor) (F31 DA028020 Pre-doctoral Fellowship for Brian Neurocircuitry plasticity after cocaine seeking NIH/NRSA	R. Lee) \$ 103,655
03/11-02/16	(Co-N	Mentor) (PI Yanhua Huang) Regulation of nucleus accumbens neurons by sleep depriv NIH K99/R00 (DA029565-01)	vation \$ 784,584

07/18-06/23 (Mentor) (PI Postdoc Jordan Blacktop) Role of Lateral Hypothalamic Area Perineuronal Nets in the Reinstatement of Cocaine-Seeking Behavior NIH K99/R00 (DA045082) \$ 963,288 (direct + ICR) Funded-Intramural 07/90-07/91 (PI) Cocaine and Stress-Induced Changes in Rat Brain Dopamine \$ 14,393 WSU-Alcohol and Drug Abuse Research Program 07/91-07/92 (PI) Molecular Mechanisms of Cocaine-Induced Sensitization in Brain Dopaminergic Systems. WSU-Alcohol and Drug Abuse Research Program \$ 16,872 01/01-5/03 (PI) Effect of Electroconvulsive Seizure on Relapse to Cocaine-Seeking Behavior in Rats WSU Alcohol and Drug Abuse Research Program \$ 25,000 07/03-12/04 (Co-I—Heiko Jansen, WSU, PI) Role of the Circadian Pacemaker in Cocaine-addicted Relapse WSU Alcohol and Drug Abuse Research Program \$ 24,983 (Mentor) to Travis Brown-Graduate Student Support Fellowship 03/05-09/06 Cocaine Reinstatement and Brain Extracellular Matrix WSU Alcohol and Drug Abuse Research Program \$ 12,000 (PI) Reconsolidation and Disruption of Cocaine-associated Memories 01/09-11/10 WSU Alcohol and Drug Abuse Research Program \$ 35,000 07/10 (Co-PI—Heiko Jansen, WSU, PI) Equipment grant WSU Alcohol and Drug Abuse Research Program \$ 33,778 03/12 (PI) Equipment grant WSU Alcohol and Drug Abuse Research Program \$ 11,700 01/14-06/15 (PI) Adenosine: Linking Cocaine Addiction to Sleep Abnormalities WSU Alcohol and Drug Abuse Research Program \$ 24,434 06/14-09/14 (Mentor) to Megan Slaker-Graduate Student Support Fellowship RNA Interference to Investigate the Role of Perineuronal Nets in Cocaine-seeking Behavior WSU Alcohol and Drug Abuse Research Program \$ 10,566 07/15-01/17 (Mentor) to Dr. Jordan M. Blacktop, Postdoctoral Fellowship Role of lateral hypothalamic area perineuronal nets in cocaine selfadministration WSU Alcohol and Drug Abuse Research Program \$ 15,000 (124777)

07/16-01/18	(Mentor) to Dr. John Harkness, Postdoctoral Fellowship  Investigation of single gene knockdown-induced perineur for therapeutic potential in cocaine-seeking behavior	onal	net plasticity
	WSU Alcohol and Drug Abuse Research Program (128334)	\$	15,000
07/18-01/20	(PI) with Co-PI Dale Fortin  Targeting the Degradation of Perineuronal Nets	\$	30,000
07/19-12/19	(Mentor) to Angela Gonzalez, Ph.D. student Investigation of retrieval-extinction parameters using a variable during cocaine self-administration (135212)		tio schedule 13,207
2001-present	(Mentor) Undergraduate grants (Mentor) of 9 individuals total semester-long or summer-long projects WSU Alcohol and Drug Abuse Research Program (\$2,00		,000 each)
04/19-03/20	(Co-I) with PI Shaban Demirel  EEG activity patterns for memory updating  Legacy Research Institute Kiesow Collaboration	\$	5,000
04/22-03/24	(PI) Impact of FDA-approved ketamine for reducing relapse is model for cocaine addiction Good Samaritan Foundation of Legacy Health		animal 278,030
04/22-03/24	<ul> <li>(PI) Non-invasive rhythmic brain stimulation to reduce relapse model of addiction Good Samaritan Foundation of Legacy Health</li> </ul>		cocaine 406,516
04/22-03/25	(PI) Impact of FDA-approved ketamine for reducing relapse in for cocaine addiction Good Samaritan Foundation of Legacy Health		animal model 623,505

## **Invited Presentations:**

- 1. Symposium on Relationship of Sensitization to Animal Models of Psychosis; 17<sup>th</sup> Congress of Collegium Internationale Neuro-Psychopharmacologicum; Kyoto, Japan. 1990.
- 2. Symposium on Animal Models of Psychosis; C.I.N.P. Satellite Symposium on Trends in Schizophrenia and Mood Disorders Research; Kyoto, Japan. 1990.
- 3. Department of Biological Sciences, University of Idaho; Moscow, ID. 1990.
- 4. National Conference of Chemical Sensitivity and Low Chemical Exposure; Baltimore, MD. 1994.
- 5. Laboratoire de Psychobiologie des Comportements Adaptatifs; INSERM, Universite de Bordeaux; Bordeaux, France. 1994.

- 6. Workshop on Animal Models of Nervous System Susceptibility to Indoor Air Contaminants; U.S. EPA; Chapel Hill, NC. 1994.
- 7. Workshop on Multiple Chemical Sensitivity; Health Effects Institute; Cambridge, MA. 1995.
- 8. Conference on Risk Assessment Issues for Sensitive Human Populations; Dayton, OH. 1995.
- 9. Workshop on Experimental Approaches to Chemical Sensitivity; Environmental and Occupational Health Sciences Institute; Princeton, NJ. 1995.
- 10. 37<sup>th</sup> Occupational Health and Preventative Medicine Workshop; U.S. Navy; Virginia Beach, VA. 1996.
- 11. Department of Biological Sciences, University of Idaho; Moscow, ID. 1996.
- 12. NIDA meeting: "Stress, the CRF System and Drugs of Abuse", Washington, D.C. 1998.
- 13. Department of Medicine-Respiratory Sciences, University of Arizona Health Sciences Center, Tucson, AZ. 1998.
- 14. American Chemical Society, Symposium on Multiple Chemical Sensitivity, Boston, MA. 1998.
- 15. University of Bergen, Symposium on Sensitization/Somatization, Bergen, Norway. 1998.
- 16. Center for Disease Control, The Health Impact of Chemical Exposures During the Gulf War: A Research Planning Conference, Atlanta, 1999.
- 17. Washington State Weed Association, Yakima, WA. 1999.
- 18. Environmental Sensitivities Research Institute Conference, Herndon, VA. 1999.
- 19. Role of Neural Plasticity in Chemical Intolerance, New York Academy of Sciences Conference, (Principle Co-organizer), New York, NY. 2000.
- 20. National Institute on Drug Abuse weekly seminar series, Baltimore, MD. 2000.
- 21. Department of Pharmacology and Therapy, LSU Medical Center, Shreveport, LA. 2001.
- 22. University of Tennessee Health Science Center, Department of Pharmacology, Memphis, TN. 2003.
- 23. National Institutes of Environmental Health Sciences: Addiction and Chemical Intolerance: A Shared Etiology? (Meeting Co-organizer), North Carolina. 2005.
- 24. National Institute on Drug Abuse: Frontiers in Addiction Research (Chair): Reconsolidation of Memory: A New Approach to Treat Drug Addiction? Washington, D.C. 2005.
- 25. Medical University of South Carolina, Department of Neurosciences, Charleston, SC. 2008.
- 26. University of Chicago, Department of Psychiatry and Behavioral Neuroscience, Chicago, IL. 2011.
- 27. Washington State University Spokane Riverpoint Campus, Spokane, WA. 2011.
- 28. Oregon Health & Science University, Behavioral Neuroscience, Portland, OR, 2012.
- 29. University of Wyoming, School of Pharmacy, Laramie, WY, 2012.
- 30. Legacy Research Institute, Portland, OR, 2013
- 31. Pavlovian Society, Portland, OR, 2015

- 32. Macquarie University Human Sciences Perspectives Workshop, Sydney, Australia, 2015
- 33. University of New South Wales Inter-University Meeting (Keynote Speaker) Sydney, Australia, 2015
- 34. American College of Neuropsychopharmacology (ACNP), Hollywood, FL, 2015.
- 35. Washington State University, Sleep and Performance Research Center, Spokane, 2016
- 36. Oregon Chapter, Society for Neuroscience, Portland, OR, 2016
- 37. National Institute on Drug Abuse NIDA-NIAAA Neuroscience Consortium Cutting-Edge Seminar, Bethesda, MD, 2016
- 38. Netherlands Institute of Neuroscience, Amsterdam, Netherlands, 2016
- 39. Jaume I University, Castellon, Spain, 2016
- 40. John van Geest Centre for Brain Repair (James Fawcett special group meeting with PIs from UK and Spain), University of Cambridge, Cambridge, UK, 2016
- 41. Labroots Neuroscience Virtual Conference, March, 2017
- 42. WSU Spokane College of Medicine Retreat, Spokane, WA, May, 2017 internal
- 43. Research Society on Alcoholism, Denver, CO, June, 2017
- 44. WSU Translational Addiction Research Center, September, Vancouver, WA, 2017 internal
- 45. Legacy Research Institute, Portland, OR, October, 2017
- 46. Controlling Neuronal Plasticity, Prague, Czech Republic, December, 2018
- 47. University of Wyoming, Laramie, WY, May, 2019
- 48. Oregon Health & Science University, Portland, OR, September, 2019
- 49. West Virginia University Health Sciences Center, Morgantown, WV, October, 2019
- 50. Research Society on Alcoholism, June, 2021
- 51. Oregon Health & Science University, Portland, OR, October, 2021
- 52. University of Mississippi Medical Center, Jackson, MS, October, 2022
- 53. International Conference on Learning and Memory, Huntington Beach, CA, April, 2023
- 54. College on Problems of Drug Dependence, Denver, CO, June, 2023

#### **Principal Organizer or Co-organizer:**

New York Academy of Sciences-sponsored meeting entitled "Role of Neural Plasticity in Chemical Intolerance". June 16-19, 2000, Rockefeller University, NY. (Co-organizer, Chair)

National Institute of Environmental Health Sciences: "Addiction and Chemical Intolerance: A Shared Etiology?" September, 2005, North Carolina (Co-organizer)

National Institute on Drug Abuse: Frontiers in Addiction Research: "Reconsolidation of Memory: A New Approach to Treat Drug Addiction?" November, 2005 (Organizer and Chair)

Society for Neuroscience Mini-symposium "Casting a Wide Net: Role of Perineuronal Nets in Neural Plasticity" October, 2016 (Organizer and Chair)

Winter Conference on Brain Panel "Net Gain and Loss: Perineuronal Nets, Plasticity, and Drugs of Abuse" January, 2018 (Organizer and Chair)

Society for Neuroscience Nanosymposium "Circuitry and Cell-Type Specific Neurophysiology of Addiction" November, 2018 (Co-chair)

College on Problems of Drug Dependence Symposium "Circadian and Sleep Factors in Substance Use Disorder: Role of the Extracellular Matrix", June, 2022 (Organizer and Chair)

*International Conference on Learning and Memory* "Role of interneurons in learning and memory: Relevance to psychiatric disorders", April, 2023 (Organizer and Chair)

## Papers (Refereed): (1/23: citations: 6,646; H-index 44)

- 1. **Sorg, B.A.**, D. Agrawal, H.C. Agrawal and A.T. Campagnoni (1986). Expression of myelin proteolipid protein and basic protein in normal and dysmyelinating mutant mice. *J. Neurochem.* 46: 379-387.
- 2. **Sorg, B.A.**, M.M. Smith and A.T. Campagnoni (1987). Developmental expression of the myelin proteolipid protein and basic protein mRNAs in normal and dysmyelinating mutant mice. *J. Neurochem.* 49: 1146-1154.
- 3. Campagnoni, A.T., **B.A. Sorg**, H.J. Roth, K. Kronquist, S.L. Newman, K. Kitamura, C.W. Campagnoni and B.F. Crandall (1987). Expression of myelin protein genes in the developing brain. *J. Physiol*. (Paris, France) 82: 229-238.
- 4. **Sorg, B.A.**, N.S. Magnuson and R. Reeves (1989). Effect of dexamethasone on the expression of interleukin-2 in a mouse T cell line. *Intl. J. Biochem.* 21: 961-970.
- 5. **Sorg, B.A.** and P.W. Kalivas (1991). Effects of cocaine and footshock stress on extracellular dopamine levels in the ventral striatum. *Brain Res.* 559: 29-36.
- 6. See, R.E., **B.A. Sorg,** M.A. Chapman and P.W. Kalivas (1991). *In vivo* assessment of dopamine release and metabolism in the ventral striatum of awake rats following administration of dopamine D1 and D2 receptor agonists and antagonists. *Neuropharmacology* 30: 1269-1274.
- 7. **Sorg, B.A.** and P. Whitney (1992). Effect of trait anxiety and situational stress on working memory capacity. *J. Res. Personality* 26: 235-241.
- 8. **Sorg, B.A** (1992). Mesocorticolimbic dopamine systems: Cross-sensitization between stress and cocaine. *Ann. NY Acad. Sci.* 654: 136-144.
- 9. **Sorg B.A.** and P.W. Kalivas (1993). Effects of cocaine and footshock stress on extracellular dopamine levels in the medial prefrontal cortex. *Neuroscience* 5: 695-703.
- 10. **Sorg, B.A.**, S.-Y. Chen and P.W. Kalivas (1993). Time course of tyrosine hydroxylase expression following behavioral sensitization to cocaine. *J. Pharmacol. Exp. Ther*. 266(1):424-430.
- 11. Kalivas, P.W., M.S. Hooks and **B.A. Sorg** (1993). The pharmacology and neural circuitry involved of sensitization to psychostimulants. *Behav. Pharmacol.* 4: 315-334.
- 12. Hooks, M.S., **B.A. Sorg** and P.W. Kalivas (1994). The relationship between mRNA levels and the locomotor response to novelty. *Brain Res.* 663: 312-316.

- 13. **Sorg, B.A.**, M.S. Hooks and P.W. Kalivas (1994). Neuroanatomy and neurochemical mechanisms of time-dependent sensitization. *Toxicol. Indust. Health* 10: 369-386.
- 14. **Sorg, B.A.** and C. Ulibarri (1995). Application of a protein synthesis inhibitor into the ventral tegmental area but not the nucleus accumbens, prevents behavioral sensitization to cocaine. *Synapse* 20: 217-224.
- 15. **Sorg, B.A.**, B.J.M. Guminski, M.S. Hooks and P.W. Kalivas (1995). Cocaine alters glutamic acid decarboxylase mRNA differentially in the nucleus accumbens core and shell. *Mol. Brain Res.* 29: 381-386.
- 16. Prasad, B.M., **B.A. Sorg**, C. Ulibarri and P.W. Kalivas (1995). Sensitization to stress and psychostimulants: Involvement of dopamine transmission versus the HPA axis. *Ann. NY Acad. Sci.* 771: 617-625.
- 17. Prasad, B.M., C. Ulibarri, P.W. Kalivas and **B.A. Sorg** (1996). Effect of adrenalectomy on the initiation and expression of cocaine-induced sensitization. *Psychopharmacol*. 125: 265-273.
- 18. See, R.E., A.M. Lynch and **B.A. Sorg** (1996). Subchronic administration of clozapine, but not haloperidol and metoclopramide, decreases dopamine D2 receptor mRNA levels in the nucleus accumbens and caudate putamen in rats. *Neuroscience* 72: 99-104.
- 19. **Sorg, B.A.**, J.R. Willis, T.C. Nowatka, C. Ulibarri, R.E. See, and H.H. Westberg (1996). Proposed animal neurosensitization model for MCS in studies with formaldehyde. *Toxicology* 111:135-145.
- Sorg, B.A., and B.M. Prasad (1997). Potential role of stress and sensitization in the development and expression of multiple chemical sensitivity. *Env. Health Persp. S2* 105:539-547.
- 21. Bell, I.R., J. Rossi III, M.E. Gilbert, G. Kobal, L.A. Morrow, D.B. Newlin, **B.A. Sorg** and R.W. Wood (1997). Testing the neural sensitization and kindling hypothesis for illness from low levels of environmental chemicals. *Env. Health Persp. S2* 105:539-547.
- 22. **Sorg, B.A.**, D.L. Davidson, P.W. Kalivas, and B.M. Prasad (1997). Repeated cocaine alters cocaine-induced increase in extracellular dopamine levels in the medial prefrontal cortex. *J. Pharm. Exp. Ther.* 281:54-61.
- 23. Meiergerd, S.M., J.O. Schenk, and **B.A. Sorg** (1997). Repeated cocaine and stress increase dopamine clearance in the rat medial prefrontal cortex. *Brain Res*.773:203-207.
- 24. Kalivas, PW, RC Pierce, J Cornish and **BA Sorg** (1998). A role for sensitization in craving and relapse in cocaine addiction. *J Psychopharmacol* 12:49-53.
- 25. Prasad, B.M., C. Ulibarri, and **B.A. Sorg** (1998). Stress-induced cross-sensitization to cocaine: Effect of adrenalectomy and corticosterone after short- and long-term withdrawal. *Psychopharmacol.* 136:24-33.
- 26. **Sorg, B.A.**, J.R. Willis, R.E. See, B. Hopkins, and H.H. Westberg (1998). Repeated low-level formaldehyde exposure produces cross-sensitization to cocaine: Possible relevance to chemical sensitivity in humans. *Neuropsychoparmacol.* 18:385-394.
- 27. Prasad, B.M., T. Hochstatter and **B.A. Sorg** (1999). Expression of cocaine sensitization: regulation by the medial prefrontal cortex. *Neuroscience* 88: 765-774.

- 28. **Sorg, BA,** and T Hochstatter. (1999). Behavioral sensitization after repeated formaldehyde exposure in rats. *Toxicol. Indust. Health* 15:346-55.
- 29. **Sorg, B.A.** (1999). Multiple chemical sensitivity: potential role for neural sensitization. *Crit. Rev. Neurobiol.* 13:283-316 (invited review).
- 30. Wayment, H.K., J.O. Schenk, and **B.A. Sorg**. (2001). Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition. *J. Neurosci.* 21:35-44
- 31. **Sorg, BA**, N. Li and W.-R. Wu. (2001). Dopamine D1 receptor activation in the medial prefrontal cortex prevents the expression of cocaine sensitization. *J. Pharmacol. Exp. Ther.* 297:501-508.
- 32. **Sorg, B.A.,** T.M. Bailie, M.L. Tschirgi, N.Li and W.-R. Wu. (2001). Exposure to repeated low-level formaldehyde in rats increases basal corticosterone levels and enhances the corticosterone response to subsequent formaldehyde. *Brain Res.* 898:314-320.
- 33. Sanchez, C.J. and **B.A. Sorg**. (2001) Conditioned fear stimuli reinstate cocaine-induced conditioned place preference. *Brain Res.* 908:86-92.
- 34. **Sorg**, B.A., M.L. Tschirgi, S. Swindell, L. Chen and J. Fang (2001). Repeated formaldehyde effects in an animal model for multiple chemical sensitivity. *Ann. NY Acad. Sci.* 933:57-67.
- 35. **Sorg, B.A.** and D.B. Newlin, (2002) Sensitization as a mechanism for multiple chemical sensitivity: relationship to evolutionary game theory. *Scand. J. Psychol.* 43:161-167.
- 36. Wu, W.-R., N. Li and **B.A. Sorg.** (2002) Regulation of medial prefrontal cortex dopamine response to acute and repeated cocaine: effect of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptors. *Neurosci.* 114:507-516.
- 37. **Sorg, BA**, DL Davidson, T Hochstatter and PW Sylvester (2002) Repeated cocaine decreases the avoidance response to a novel aversive stimulus. *Psychopharmacol*. 163:9-19.
- 38. Sanchez, CJ, TM Bailie, W-R Wu, N Li and **BA Sorg** (2003) Manipulation of D1-like receptor activation in the rat medial prefrontal cortex alters stress- and cocaine-induced reinstatement of conditioned place preference behavior. *Neurosci.* 119:497-505.
- 39. Wu, WR, N Li and **BA Sorg** (2003) Prolonged effects of repeated cocaine on medial prefrontal cortex dopamine response to cocaine and natural predatory odor challenge in rats. *Brain Res* 991:232-239.
- 40. **Sorg, BA**, S. Swindell and ML Tschirgi. (2004) Repeated low-level formaldehyde exposure produces enhanced fear conditioning to odor in male, but not female, rats. *Brain Res.* 1008:11-19.
- 41. **Sorg, BA**, N Li and WR Wu. (2004) Activation of dopamine D1 receptors in the medial prefrontal cortex produces bidirectional effects on cocaine-induced locomotor activity in rats: effects of repeated stress *Neurosci*. 127:187-196.
- 42. Sleipness, EP, **BA Sorg** and HT Jansen. (2005) Time of day alters long-term sensitization to cocaine in rats. *Brain Res.* 1065:132-137. PMID: 16309631
- 43. Cloutier, S, MR Forquer and **BA Sorg**. (2006) Low level lindane exposure alters extinction of conditioned fear in rats. *Toxicol*. 217:147-154.

- 44. Carter K, K Lukowiak, JO Schenk and **BA Sorg.** (2006) Repeated cocaine effects on learning, memory and extinction in the pond snail *Lymnaea stagnalis*. *J. Exp. Biol*. 209: 4273-4282. PMID: 17050842
- 45. Sleipness EP, **BA Sorg** and HT Jansen. (2007) Diurnal differences in dopamine transporter and tyrosine hydroxylase levels in rat brain: dependence on the suprachiasmatic nucleus. *Brain Res.* 1129: 34-42. PMID: 17156761
- 46. Brown TE, MR Forquer, DL Cocking, HT Jansen, JW Harding and **BA Sorg**. (2007) Role of matrix metalloproteinases in the acquisition and reconsolidation of cocaine-induced conditioned place preference. *Learn. Mem.* 14: 214-223. PMCID: PMC1838561
- 47. Sleipness EP, **BA Sorg**, Jansen HT. (2007) Contribution of the suprachiasmatic nucleus to day:night variation in cocaine-seeking behavior. *Physiol Behav* 91:523-530. PMID: 17573077
- 48. Huang YH, Lin Y, Brown TE, Han MH, Saal DB, Neve RL, Zukin RS, **BA Sorg**, Nestler EJ, Malenka RC, Dong Y. (2008) CREB modulates the functional output of nucleus accumbens neurons: a critical role of N-methyl-D-aspartate glutamate receptor (NMDA) receptors. *J Biol Chem* 283:2751-2760, PMCID: PMC2535571
- 49. Bjorklund NL, **BA Sorg**, Schenk JO. (2008) Neuronal dopamine transporter activity, density and methamphetamine inhibition are differentially altered in the nucleus accumbens and striatum with no changes in glycosylation in rats behaviorally sensitized to methamphetamine. *Synapse* 62:736-745. PMID: 18651643
- 50. Sleipness EP, Jansen HT, Schenk JO, **BA Sorg**. (2008) Time-of-day differences in dopamine clearance in the rat medial prefrontal cortex and nucleus accumbens. *Synapse* 62:877-885. PMCID: PMC3031299
- 51. Brown TE, Forquer MR, Harding JW, Wright JW, **BA Sorg**. (2008) Increase in matrix metalloproteinase-9 levels in the rat medial prefrontal cortex after cocaine reinstatement of conditioned place preference. *Synapse* 62:886-889. PMID: 18792988
- 52. Brown TE, Lee BR, **BA Sorg**. (2008) The NMDA antagonist MK-801 disrupts reconsolidation of a cocaine-associated memory or conditioned place preference but not for self-administration in rats. *Learn Mem* 15:857-865. PMCID: PMC2632842
- 53. Brown TE, AR Wilson, DL Cocking, **BA Sorg**. (2009) Inhibition of matrix metalloproteinase activity disrupts reconsolidation but not consolidation of a fear memory. *Neurobiol Learn Mem* 91:66-72. PMCID: PMC2719776
- 54. Mu P, T Fuchs, DB Saal, **BA Sorg**, Y Dong, J Panksepp. (2009) Repeated cocaine induces sensitization of ultrasonic vocalization in rats. *Neurosci Lett* 453:31-35. PMCID: PMC2680749
- 55. Wright JW, PC Meighan, TE Brown, RV Wiediger, **BA Sorg**, JW Harding. (2009) Habituation-induced neural plasticity in the hippocampus and prefrontal cortex mediated by MMP-3. *Behav Brain Res* 203:27-34.
- 56. Huang YH, Y Lin, P Mu, BR Lee, TE Brown, G Wayman, H Marie, W Liu, Z Yan, **BA Sorg**, OM Schlüter, RS Zukin, Y Dong. (2009) In vivo cocaine experience generates silent synapses *Neuron* 63:40-47. PMCID: PMC2721479
- 57. Mu P, J Moyer, M Ishikawa, Y Zhang, J Panksepp, **BA Sorg**, O Schlüter, Y Dong. (2010) Exposure to cocaine dynamically regulates the intrinsic membrane excitability of nucleus accumbens neurons. *J Neurosci* 30:3689-3699. PMCID: PMC2853189

- 58. Kennedy, CD, SW Houmes, KL Wyrick, SM Kammerzell, K Lukowiak, **BA Sorg** (2010) Methamphetamine enhances memory of operantly-conditioned respiratory behavior in the snail Lymnaea stagnalis. *J Exp Biol* 213:2055-2065. PMID: 20511519
- 59. Cearley, CN, K Blindheim, **BA Sorg**, JM Krueger, L Churchill (2011) Acute cocaine increases interleukin-1β mRNA and immunoreactive cells in the cortex and nucleus accumbens. *Neurochem. Res.* 36:686-692. PMID: 21399909
- 60. **Sorg, BA**, G Stark, A Sergeeva and HT Jansen (2011) Photoperiodic suppression of drug reinstatement. *Neuroscience* 176:284-295. PMCID: PMC3040258
- 61. Brown TE, B Lee, P Mu, D Ferguson, D Dietz, Y Ohnishi, Y Lin, A Suska, M Ishikawa, Y Huang, H-W Shen, PW Kalivas, **BA Sorg**, RS Zukin, E Nestler, Y Dong, O Schlüter (2011) A silent synapse-based mechanism for cocaine-induced locomotor sensitization. *J Neurosci* 31:8163-8174. PMCID: PMC3286116
- 62. Browning JR, DA Browning, AO Maxwell, Y Dong, HT Jansen, J Panksepp, **BA Sorg** (2011) Positive affective vocalizations during cocaine and sucrose self-administration: A model for spontaneous drug desire in rats *Neuropharmacol* 61: 268-275. PMCID: PMC3115664
- 63. **Sorg, BA** (2012) Reconsolidation of drug memories. *Neurosci Biobehav Rev.* 36: 1400-1417. PMCID: PMC3526670
- 64. Jansen, HT, A Sergeeva, G Stark, **BA Sorg** (2012). Circadian discrimination of reward: evidence for simultaneous yet separable food- and drug-entrained rhythms in the rat. *Chronobiol Intl* 29:454-468. PMID: 22475541
- 65. Sanchez, EJ, RP Hayes, BN Webb, AK Subramanian, MS Nissen, JT Barr, JP Jones, EA Shelden, **BA Sorg**, M Fill, JO Schenk, C Kang (2013). Potential role of cardiac calsequestrin in the lethal arrhythmic effects of cocaine. *Drug Alc Depend* 133:344-351. PMCID: PMC4097383
- 66. Browning, JR, HT Jansen, and **BA Sorg** (2014). Inactivation of the paraventricular thalamus abolishes the expression of cocaine conditioned place preference in rats. *Drug Alc Depend* 134: 387-390. PMCID: PMC3910376
- 67. Lukowiak K, B Heckler, TE Bennett, EK Schriner, K Wyrick, C Jewett, RP Todd, and **BA Sorg** (2014) Enhanced memory persistence is blocked by a DNA methyltransferase inhibitor in the snail *Lymnaea stagnalis*. *J Exp Biol* 217:2920-2929. PMID: 24902747
- 68. **Sorg BA**, RP Todd, M Slaker and L Churchill (2015) Anisomycin in the medial prefrontal cortex reduces reconsolidation of cocaine-associated memories in the rat self-administration model. *Neuropharmacol* 92:25-33. PMCID: PMC4346388
- 69. Slaker M, L Churchill, RP Todd, JM Blacktop, DG Zuloaga, J Raber, RA Darling, TE Brown, and **BA Sorg** (2015) Removal of perineuronal nets in the medial prefrontal cortex impairs the acquisition and reconsolidation of cocaine-conditioned place preference. *J Neurosci* 35:4190-4202. PMCID: PMC4355195
- 70. Slaker, M, JM Blacktop, and **BA Sorg** (2016) Caught in the net: Perineuronal nets and addiction. *Neural Plasticity* (Invited review) PMC4745418
- 71. Zhang, X, VM Chiu, RP Todd, **BA Sorg**, and HH Hill (2016) Neuronal metabolomics by ion mobility mass spectrometry in cocaine self-administering rats after early and late withdrawal. *Analyt Bioanalyt Chem* 408:4233-4245 PMID: 27108279.

- 72. **Sorg, BA**, S Berretta, JM Blacktop, JW Fawcett, H Kitagawa, JCF Kwok and M Miquel. (2016) Casting a wide net: role of perineuronal nets in neural plasticity. *J Neurosci* 36:11459-11468. PMID: 27911749.
- 73. Slaker, ML, J Harkness and **BA Sorg** (2016) A standardized and automated method of perineuronal net analysis using *Wisteria floribunda* agglutinin staining intensity. *IBRO Reports* 1:54-60. PMID: 28713865
- 74. Slaker, ML, J Barnes, **BA Sorg** and JW Grimm (2016) Impact of environmental enrichment on perineuronal nets in the prefrontal cortex following early and late abstinence from sucrose self-administration in rats. *PLOS ONE* 11:e0168256. PMID: 27977779
- 75. Blacktop, JM, RP Todd and **BA Sorg** (2017) Role of perineuronal nets in the anterior dorsal lateral hypothalamic area in the acquisition of cocaine-induced conditioned place preference and self-administration. *Neuropharmacol*, 118:124-136.
- 76. Dingess PM, Harkness JH, Slaker M, **Sorg BA**, and Brown TE (2018) Consumption of a high fat diet alters perineuronal nets in the prefrontal cortex. *Neural Plasticity*, PMID: 29849552.
- 77. Blacktop, JM and **BA Sorg** (2019) Perineuronal nets in the lateral hypothalamus area regulate cue-induced reinstatement of cocaine seeking behavior. *Neuropsychopharmacol* PMID: 30258113.
- 78. Slaker, ML, ET Jorgensen, DM Hegarty, X Liu, Y Kong, F Zhang, RJ Linhardt, TE Brown, SA Aicher and **BA Sorg**. (2018) Cocaine exposure modulates perineuronal nets and synaptic excitability of fast-spiking interneurons in the medial prefrontal cortex. *eNeuro* 0221-18.2018. PMID: 30294670.
- 79. Su, W., S. Matsumoto, **B. Sorg,** and L.S. Sherman (2019) Distinct roles for hyaluronan in neural stem cell niches and perineuronal nets. *Matrix Biology* 78-79:272-283. PMCID: PMC6068007.
- 80. Harkness, JH, PN Bushana, RP Todd, WC Clegern, **BA Sorg** and JP Wisor (2019) Sleep disruption elevates oxidative stress in parvalbumin-positive cells of the rat cerebral cortex. *Sleep* PMID: 30371896.
- 81. Hegarty, DM, AE Gonzalez, JH Harkness, **BA Sorg** and SA Aicher (2019) Quantitative anatomical approaches to examining plasticity in neural circuites. Microsc Microanal. 25 (Suppl 2) 1124-1125. PMID: 36644160.
- 82. Dingess, PM, Z. Zhaojie, **BA Sorg**, CR Ferrario, and TE Brown (2020) Sex- and region-specific effects of high fat diet on PNNs in obesity susceptible rats. *Physiol Behav*222:112963. PMID: 32416158.
- 83. Jorgenson, EJ, AE Gonzalez, JH Harkness, DM Hegarty, A Thakar, DJ Burchi, JA Aadland, SA Aicher, **BA Sorg** and TE Brown (2021) Cocaine memory reactivation induces functional adaptations within parvalbumin interneurons in the rat medial prefrontal cortex. *Addiction Biol* (e12947) PMID: 32750200.
- 84. Reyes, K-A, PS Kudva, B Heckler, AE Gonzalez, and **BA Sorg** (2021) Rat ultrasonic vocalization as an index of memory. *Neurosci Lett* 741:135458 PMCID: PMC7750257.
- 85. Harkness, JH, AE Gonzalez, PN Bushana, ET Jorgensen, DM Hegarty, AA Di Nardo, A Prochiantz, JP Wisor, SA Aicher, TE Brown, and **BA Sorg**. (2021) Diurnal changes in

- perineuronal nets and parvalbumin neurons in the rat medial prefrontal cortex. *Brain Structure & Function* 226:1135 PMCID: PMC8086998.
- 86. Wingert, JC, and **BA Sorg** (2021) Impact of perineuronal nets on electrophysiology of parvalbumin interneurons, principal neurons, and brain oscillations: A review. *Front Synaptic Neurosci* 13:673210. PMCID: 34040511.
- 87. Fawcett, JW, M Fyhn, P Jendelova, JCF Kwok, J Ruzicka, and **BA Sorg** (2022) The extracellular matrix and perineuronal nets in memory. *Mol Psychiatry* Jun 27 PMID: 35760878.
- 88. Brown, TE, and **BA Sorg** (2023) Net gain and loss: Influence of natural rewards and drugs of abuse on perineuronal nets. *Neuropsychopharmacol* PMID: 35568740.
- 89. Gonzalez, AE, ET Jorgensen, JD Ramos, JH Harkness, JA Aadland, TE Brown and **BA Sorg** (2022) Impact of perineuronal net removal in the rat medial prefrontal cortex on parvalbumin interneurons after reinstatement of cocaine conditioned place preference. *Front Cell Neurosci*. July 28 PMC9366391.

#### **Chapters and Other Publications:**

- 1. Macklin, W.B., M.V. Gardinier, P.L. Deininger, **B.A. Sorg** and C.W. Campagnoni (1987). Myelin proteolipid protein expression in normal and jimpy mice. In: *A Multidisciplinary Approach to Myelin Diseases*. Plenum Press, New York, NY, pp. 29-46.
- 2. **Sorg, B.A.**, N.S. Magnuson and R. Reeves (1989). Regulation of interleukin-2 expression by dexamethasone in a mouse T cell line. In: *Molecular Biology of Stress*. S. Breznitz and O. Zinder, eds. Alan R. Liss, New York, NY, pp. 215-224.
- 3. Steketee, J.D., **B.A. Sorg** and P.W. Kalivas (1992). The role of the nucleus accumbens in sensitization to drugs of abuse. *Prog. Neuro-Psychopharmacol. Biol. Psychiat.* 16: 237-246.
- 4. **Sorg, B.A.** and J.D. Steketee (1992). Mechanisms of cocaine-induced sensitization. *Prog. Neuro-Psychopharm. Biol. Psychiat.* 16: 1003-1012.
- 5. **Sorg, B.A.** and P.W. Kalivas (1993). Behavioral sensitization to stress and psychostimulants: Role of dopamine and excitatory amino acids in the mesocorticolimbic system. *Seminars Neurosci.* 5: 343-350.
- 6. **Sorg, B.A.** and P.W. Kalivas (1995). Stress and neuronal sensitization. In: *Neurobiological and Clinical Consequences of Stress: From Normal Adaptation to PTSD*. M.J. Friedman, D.S. Charney and A.Y. Deutch, eds. Raven Press, pp. 83-103.
- 7. Kalivas, P.W. and **B.A. Sorg** (1996). Role of neurotransmitters in the ventral tegmental area in stress-induced activation of dopamine transmission. *NIAAA Monogram*. 29:139-144.
- 8. Kalivas, P.W. and **B.A Sorg** (1996). Animal models of psychosis reveal involvement of hippocampal-corticostrial-mesencephalic circuitry. In: *Dopamine Disease States*. R.J. Beninger, T. Palomo and T. Archer, eds. CYM Press, Madrid, Spain. pp. 463-475.
- 9. Kalivas, P.W., R.C. Pierce and **B.A. Sorg** (1999). A role for sensitization in psychostimulant-induced paranoia and psychosis. In: *Interactive Monaminergic Disorders*. RJ Beninger, T Palomo, and T Archer, eds. CYM Press: Madrid, Spain; pp. 453-460

- 10. Keegan, R.D., L. Shuang, **B.A. Sorg** and R.M. Quock (2003) The role of nitric oxide in locomotor regulation in mice and its interaction with nitrous oxide. *Proc. West. Pharmacol. Soc.* 46:114-115.
- 11. **Sorg, B.A.,** T.M. Bailie and N. Li (2011) Dopamine receptor stimulation or blockade in the medial prefrontal cortex suppresses extinction of a conditioned fear response in rats. In: *Psychology of Fear: New Research (Psychology of Emotions, Motivations and Actions)* Allen D. Gervaise, Ed., Elsevier, pp 83-94. (Invited chapter).
- 12. **Sorg, B.A.** and T.E. Brown (2012) Matrix metalloproteinases, memory consolidation, reconsolidation, and drugs of abuse. In: *Matrix Metalloproteinases: Biology, Functions and Clinical Implications* (Oshiro, N and Miyagi, E., eds). Nova Publishers, pp. 127-150. (Invited chapter).
- 13. **Sorg, B.A.** (2013) Memory reconsolidation and drugs of abuse. In: *Biological Research on Addiction: Comprehensive Addictive Behaviors and Disorders, Vol 2* (Miller, P.M., ed) pp. 323-332 (Invited chapter).
- 14. Hegarty, D.M., A.E. Gonzalez, J.H. Harkness, **B.A. Sorg**, and S.Aicher (2019) Quantitative anatomical approaches to examining plasticity in neural circuits. Microsc. Microanal. 25 (Supple 2) doi: 10.1017/S1431927619006354.

#### **Books Edited:**

1. **Sorg, B.A.** and Bell, I.R. (2001). Role of Neural Plasticity in Chemical Intolerance. *Annals of the New York Academy of Sciences* 933:329 pp. (Conducted 100% editing for this volume)

#### Other Publications

- 1. **Sorg, B.A.** (1999) Multiple chemical sensitivities. *Agrichemical and Environmental News* 155:1-3.
- 2. **Sorg, B.A.** (1999) Multiple chemical sensitivities: understanding the phenomenon. *Washington State Weed Association*
- 3. Brain Facts: (2016) *Putting the brakes on brain changes* http://www.brainfacts.org/brain-basics/cell-communication/articles/2016/image-of-the-week-putting-the-brakes-on-brain-changes-122016/

<u>Abstracts</u>: (approximately 8-10/year; majority are Society for Neuroscience Abstracts; others: College on Problems of Drug Dependence, Winter Brain Conference, misc.)

**U.S. Patent (10603462)** with John Harkness, Ryan Todd: *Trolley for the Automation of Sleep Disruption* 

## **Grant Reviewer**

2023	Natural Sciences and Engineering Research Council of Canada (NSERC)
2021	NIH-Ad hoc; NIDA Career Development and Education, ZDA1 SKM-D
2020	NIH-Ad hoc: SEP (ZRG1 IFCN-C)
2020	Biotechnology and Biological Sciences Research Council, UK (BBSRC)

2020University of Washington Diabetes Research Center2019Neurological Foundation of New Zealand2019Netherlands Organisation for Scientific Research2018French Agence Nationale de la Recherche2016, 2017NIH Cutting-Edge Basic Research Awards (CEBRA; ZDA1 JXR-D 12 S) (ad hoc)2016, 2018Foundation for Polish Science2016WSU-Vancouver Mini-grants2015, 2019NIH BPN (Blueprint Neurotherapeutics)—Ad hoc; ZNS1 SRB-T2013, 2017Medical Research Council (UK)—Ad hoc2013NIH BRLE—Ad hoc2013, 2018Israel Science Foundation—Ad hoc2012NIH-MB Study Section, <b>Standing Member</b> 2012NIH-Ad hoc: NMB and ZRG1 IFCN-L2011NSF—Ad hoc2011NSF—Ad hoc2011NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1 JXR-D - program projects2006-2009NIH Ad hoc: NIDA-L, ZDA1 RXL-E and NMB (2008), ZDA1 GMX-A and ZDA1 GMX-A (2009) ZDA1999-2005NIH (NIDA) <b>Standing Member</b> , Medications Development (SEP Chair, 2002)1999NIH (NIDA) Medications Development Special Emphasis PanelU.S. Army Medical Research and Materiel Command, Ad-hoc1993-presentUs. Army Medical Research and Materiel Command, Program1997-1998Washington State University Alcohol and Drug Abuse ProgramUniversity of Idaho EPSCoR Foundation	2020-2022	NIH BPN (Blueprint Neurotherapeutics) – Ad hoc; ZNS1 SRB-T
2019 Netherlands Organisation for Scientific Research 2018 French Agence Nationale de la Recherche 2016, 2017 NIH Cutting-Edge Basic Research Awards (CEBRA; ZDA1 JXR-D 12 S) (ad hoc) 2016, 2018 Foundation for Polish Science 2016 WSU-Vancouver Mini-grants 2015, 2019 NIH BPN (Blueprint Neurotherapeutics)—Ad hoc; ZNS1 SRB-T 2013, 2017 Medical Research Council (UK)—Ad hoc 2013 NIH BRLE—Ad hoc 2013, 2018 Israel Science Foundation—Ad hoc 2013-2019 NIH NMB Study Section, Standing Member 2012 NIH-Ad hoc: NMB and ZRG1 IFCN-L 2011 NSF—Ad hoc 2011 NSF—Ad hoc 2011 NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1 JXR-D – program projects 2006-2009 NIH Ad hoc: NIDA-L, ZDA1 RXL-E and NMB (2008), ZDA1 GMX-A and ZDA1 GMX-A (2009) ZDA 1999-2005 NIH (NIDA) Standing Member, Medications Development (SEP Chair, 2002) 1999 NIH (NIDA) Medications Development Special Emphasis Panel 1997-2004 U.S. Army Medical Research and Materiel Command, Ad-hoc 1998-1999 1993-present Washington State University Alcohol and Drug Abuse Program	2020	University of Washington Diabetes Research Center
2018 French Agence Nationale de la Recherche 2016, 2017 NIH Cutting-Edge Basic Research Awards (CEBRA; ZDA1 JXR-D 12 S) (ad hoc) 2016, 2018 Foundation for Polish Science 2016 WSU-Vancouver Mini-grants 2015, 2019 NIH BPN (Blueprint Neurotherapeutics)—Ad hoc; ZNS1 SRB-T 2013, 2017 Medical Research Council (UK)—Ad hoc 2013 NIH BRLE—Ad hoc 2013, 2018 Israel Science Foundation—Ad hoc 2013-2019 NIH NMB Study Section, Standing Member 2012 NIH-Ad hoc: NMB and ZRG1 IFCN-L 2011 NSF—Ad hoc 2011 NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1 JXR-D – program projects 2006-2009 NIH Ad hoc: NIDA-L, ZDA1 RXL-E and NMB (2008), ZDA1 GMX-A and ZDA1 GMX-A (2009) ZDA 1999-2005 NIH (NIDA) Standing Member, Medications Development (SEP Chair, 2002) 1999 NIH (NIDA) Medications Development Special Emphasis Panel 1997-2004 U.S. Army Medical Research and Materiel Command, Ad-hoc 1998-1999 1993-present Washington State University Alcohol and Drug Abuse Program	2019	Neurological Foundation of New Zealand
2016, 2017 NIH Cutting-Edge Basic Research Awards (CEBRA; ZDA1 JXR-D 12 S) (ad hoc)  2016, 2018 Foundation for Polish Science 2016 WSU-Vancouver Mini-grants 2015, 2019 NIH BPN (Blueprint Neurotherapeutics)—Ad hoc; ZNS1 SRB-T 2013, 2017 Medical Research Council (UK)—Ad hoc 2013 NIH BRLE—Ad hoc 2013, 2018 Israel Science Foundation—Ad hoc 2013-2019 NIH NMB Study Section, Standing Member 2012 NIH-Ad hoc: NMB and ZRG1 IFCN-L 2011 NSF—Ad hoc 2011 NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1 JXR-D – program projects 2006-2009 NIH Ad hoc: NIDA-L, ZDA1 RXL-E and NMB (2008), ZDA1 GMX-A and ZDA1 GMX-A (2009) ZDA 1999-2005 NIH (NIDA) Standing Member, Medications Development (SEP Chair, 2002) 1999 NIH (NIDA) Medications Development Special Emphasis Panel 1997-2004 U.S. Army Medical Research and Materiel Command, Ad-hoc 1998-1999 1993-present Washington State University Alcohol and Drug Abuse Program	2019	Netherlands Organisation for Scientific Research
(ad hoc)  2016, 2018 Foundation for Polish Science  2016 WSU-Vancouver Mini-grants  2015, 2019 NIH BPN (Blueprint Neurotherapeutics)—Ad hoc; ZNS1 SRB-T  2013, 2017 Medical Research Council (UK)—Ad hoc  2013 NIH BRLE—Ad hoc  2013, 2018 Israel Science Foundation—Ad hoc  2013-2019 NIH NMB Study Section, <b>Standing Member</b> 2012 NIH-Ad hoc: NMB and ZRG1 IFCN-L  2011 NSF—Ad hoc  2011 NSF—Ad hoc  2011 NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1 JXR-D – program projects  2006-2009 NIH Ad hoc: NIDA-L, ZDA1 RXL-E and NMB (2008), ZDA1 GMX-A and ZDA1 GMX-A (2009) ZDA  1999-2005 NIH (NIDA) <b>Standing Member</b> , Medications Development (SEP Chair, 2002)  1999 NIH (NIDA) Medications Development Special Emphasis Panel  1997-2004 U.S. Army Medical Research and Materiel Command, Ad-hoc  1998-1999 Department of Veterans Affairs  Washington State University Alcohol and Drug Abuse Program	2018	French Agence Nationale de la Recherche
<ul> <li>2016, 2018 Foundation for Polish Science</li> <li>2016 WSU-Vancouver Mini-grants</li> <li>2015, 2019 NIH BPN (Blueprint Neurotherapeutics)—Ad hoc; ZNS1 SRB-T</li> <li>2013, 2017 Medical Research Council (UK)—Ad hoc</li> <li>2013 NIH BRLE—Ad hoc</li> <li>2013, 2018 Israel Science Foundation—Ad hoc</li> <li>2013-2019 NIH NMB Study Section, Standing Member</li> <li>2012 NIH-Ad hoc: NMB and ZRG1 IFCN-L</li> <li>2011 NSF—Ad hoc</li> <li>2011 NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1 JXR-D – program projects</li> <li>2006-2009 NIH Ad hoc: NIDA-L, ZDA1 RXL-E and NMB (2008), ZDA1 GMX-A and ZDA1 GMX-A (2009) ZDA</li> <li>1999-2005 NIH (NIDA) Standing Member, Medications Development (SEP Chair, 2002)</li> <li>1999 NIH (NIDA) Medications Development Special Emphasis Panel</li> <li>1997-2004 U.S. Army Medical Research and Materiel Command, Ad-hoc</li> <li>1998-1999 Department of Veterans Affairs</li> <li>Washington State University Alcohol and Drug Abuse Program</li> </ul>	2016, 2017	NIH Cutting-Edge Basic Research Awards (CEBRA; ZDA1 JXR-D 12 S)
2016 WSU-Vancouver Mini-grants 2015, 2019 NIH BPN (Blueprint Neurotherapeutics)—Ad hoc; ZNS1 SRB-T 2013, 2017 Medical Research Council (UK)—Ad hoc 2013 NIH BRLE—Ad hoc 2013, 2018 Israel Science Foundation—Ad hoc 2013-2019 NIH NMB Study Section, <b>Standing Member</b> 2012 NIH-Ad hoc: NMB and ZRG1 IFCN-L 2011 NSF—Ad hoc 2011 NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1 JXR-D – program projects 2006-2009 NIH Ad hoc: NIDA-L, ZDA1 RXL-E and NMB (2008), ZDA1 GMX-A and ZDA1 GMX-A (2009) ZDA 1999-2005 NIH (NIDA) <b>Standing Member</b> , Medications Development (SEP Chair, 2002) 1999 NIH (NIDA) Medications Development Special Emphasis Panel 1997-2004 U.S. Army Medical Research and Materiel Command, Ad-hoc 1998-1999 Department of Veterans Affairs 1993-present Washington State University Alcohol and Drug Abuse Program		(ad hoc)
2015, 2019 NIH BPN (Blueprint Neurotherapeutics)—Ad hoc; ZNS1 SRB-T 2013, 2017 Medical Research Council (UK)—Ad hoc 2013 NIH BRLE—Ad hoc 2013, 2018 Israel Science Foundation—Ad hoc 2013-2019 NIH NMB Study Section, <b>Standing Member</b> 2012 NIH-Ad hoc: NMB and ZRG1 IFCN-L 2011 NSF—Ad hoc 2011 NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1 JXR-D – program projects 2006-2009 NIH Ad hoc: NIDA-L, ZDA1 RXL-E and NMB (2008), ZDA1 GMX-A and ZDA1 GMX-A (2009) ZDA 1999-2005 NIH (NIDA) <b>Standing Member</b> , Medications Development (SEP Chair, 2002) 1999 NIH (NIDA) Medications Development Special Emphasis Panel 1997-2004 U.S. Army Medical Research and Materiel Command, Ad-hoc 1998-1999 Department of Veterans Affairs 1993-present Washington State University Alcohol and Drug Abuse Program	2016, 2018	Foundation for Polish Science
2013, 2017 Medical Research Council (UK)—Ad hoc 2013 NIH BRLE—Ad hoc 2013, 2018 Israel Science Foundation—Ad hoc 2013-2019 NIH NMB Study Section, Standing Member 2012 NIH-Ad hoc: NMB and ZRG1 IFCN-L 2011 NSF—Ad hoc 2011 NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1 JXR-D – program projects 2006-2009 NIH Ad hoc: NIDA-L, ZDA1 RXL-E and NMB (2008), ZDA1 GMX-A and ZDA1 GMX-A (2009) ZDA 1999-2005 NIH (NIDA) Standing Member, Medications Development (SEP Chair, 2002) 1999 NIH (NIDA) Medications Development Special Emphasis Panel 1997-2004 U.S. Army Medical Research and Materiel Command, Ad-hoc 1998-1999 Department of Veterans Affairs 1993-present Washington State University Alcohol and Drug Abuse Program	2016	WSU-Vancouver Mini-grants
2013, 2018 Israel Science Foundation—Ad hoc 2013-2019 NIH NMB Study Section, <b>Standing Member</b> 2012 NIH-Ad hoc: NMB and ZRG1 IFCN-L 2011 NSF—Ad hoc 2011 NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1 JXR-D – program projects 2006-2009 NIH Ad hoc: NIDA-L, ZDA1 RXL-E and NMB (2008), ZDA1 GMX-A and ZDA1 GMX-A (2009) ZDA 1999-2005 NIH (NIDA) <b>Standing Member</b> , Medications Development (SEP Chair, 2002) 1999 NIH (NIDA) Medications Development Special Emphasis Panel 1997-2004 U.S. Army Medical Research and Materiel Command, Ad-hoc 1998-1999 Department of Veterans Affairs 1993-present Washington State University Alcohol and Drug Abuse Program	2015, 2019	NIH BPN (Blueprint Neurotherapeutics)—Ad hoc; ZNS1 SRB-T
2013-2019 Israel Science Foundation—Ad hoc 2013-2019 NIH NMB Study Section, <b>Standing Member</b> 2012 NIH-Ad hoc: NMB and ZRG1 IFCN-L 2011 NSF—Ad hoc 2011 NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1 JXR-D – program projects 2006-2009 NIH Ad hoc: NIDA-L, ZDA1 RXL-E and NMB (2008), ZDA1 GMX-A and ZDA1 GMX-A (2009) ZDA 1999-2005 NIH (NIDA) <b>Standing Member</b> , Medications Development (SEP Chair, 2002) 1999 NIH (NIDA) Medications Development Special Emphasis Panel 1997-2004 U.S. Army Medical Research and Materiel Command, Ad-hoc 1998-1999 Department of Veterans Affairs 1993-present Washington State University Alcohol and Drug Abuse Program	2013, 2017	Medical Research Council (UK)—Ad hoc
NIH NMB Study Section, Standing Member NIH-Ad hoc: NMB and ZRG1 IFCN-L NSF—Ad hoc NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1 JXR-D – program projects NIH Ad hoc: NIDA-L, ZDA1 RXL-E and NMB (2008), ZDA1 GMX-A and ZDA1 GMX-A (2009) ZDA NIH (NIDA) Standing Member, Medications Development (SEP Chair, 2002) NIH (NIDA) Medications Development Special Emphasis Panel U.S. Army Medical Research and Materiel Command, Ad-hoc Department of Veterans Affairs Washington State University Alcohol and Drug Abuse Program	2013	NIH BRLE—Ad hoc
NIH-Ad hoc: NMB and ZRG1 IFCN-L  NSF—Ad hoc  NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1 JXR-D – program projects  NIH Ad hoc: NIDA-L, ZDA1 RXL-E and NMB (2008), ZDA1 GMX-A and ZDA1 GMX-A (2009) ZDA  NIH Ad hoc: NIDA-L, ZDA1 RXL-E and NMB (2008), ZDA1 GMX-A and ZDA1 GMX-A (2009) ZDA  NIH (NIDA) Standing Member, Medications Development (SEP Chair, 2002)  NIH (NIDA) Medications Development Special Emphasis Panel  NSF—Ad hoc  NIH—Ad hoc: NMB and ZRG1 IFCN-L  NSF—Ad hoc  NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1  JXR-D – program projects  NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1  JXR-D – program projects  NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1  JXR-D – program projects  NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1  JXR-D – program projects  NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1  JXR-D – program projects  NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1  JXR-D – program projects  NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1  JXR-D – program projects  NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1  JXR-D – program projects  NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1  JXR-D – program projects  NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1  JXR-D – program projects  NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1  JXR-D – program projects  NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1  JXR-D – program projects  NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1  JXR-D – program projects  NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1  JXR-D – program projects  NIH (NIDA) Standing Member, Medications Development (SEP Chair, 2002)  NIH (NIDA) Medications Development Special Emphasis Panel  1997-2004  U.S. Army Medical Research and Materiel Command, Ad-hoc  1998-1999  Department of Veterans Affairs  1993-present	2013, 2018	Israel Science Foundation—Ad hoc
2011 NSF—Ad hoc 2011 NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1 JXR-D – program projects 2006-2009 NIH Ad hoc: NIDA-L, ZDA1 RXL-E and NMB (2008), ZDA1 GMX-A and ZDA1 GMX-A (2009) ZDA  1999-2005 NIH (NIDA) Standing Member, Medications Development (SEP Chair, 2002) 1999 NIH (NIDA) Medications Development Special Emphasis Panel 1997-2004 U.S. Army Medical Research and Materiel Command, Ad-hoc 1998-1999 Department of Veterans Affairs 1993-present Washington State University Alcohol and Drug Abuse Program	2013-2019	NIH NMB Study Section, Standing Member
NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1 JXR-D – program projects  NIH Ad hoc: NIDA-L, ZDA1 RXL-E and NMB (2008), ZDA1 GMX-A and ZDA1 GMX-A (2009) ZDA  NIH (NIDA) Standing Member, Medications Development (SEP Chair, 2002) NIH (NIDA) Medications Development Special Emphasis Panel  NIH (NIDA) Medical Research and Materiel Command, Ad-hoc  Department of Veterans Affairs  Washington State University Alcohol and Drug Abuse Program	2012	NIH-Ad hoc: NMB and ZRG1 IFCN-L
JXR-D – program projects  2006-2009 NIH Ad hoc: NIDA-L, ZDA1 RXL-E and NMB (2008), ZDA1 GMX-A and ZDA1 GMX-A (2009) ZDA  1999-2005 NIH (NIDA) <b>Standing Member</b> , Medications Development (SEP Chair, 2002)  1999 NIH (NIDA) Medications Development Special Emphasis Panel  1997-2004 U.S. Army Medical Research and Materiel Command, Ad-hoc  1998-1999 Department of Veterans Affairs  1993-present Washington State University Alcohol and Drug Abuse Program	2011	NSF—Ad hoc
NIH Ad hoc: NIDA-L, ZDA1 RXL-E and NMB (2008), ZDA1 GMX-A and ZDA1 GMX-A (2009) ZDA  1999-2005 NIH (NIDA) <b>Standing Member</b> , Medications Development (SEP Chair, 2002)  NIH (NIDA) Medications Development Special Emphasis Panel  1997-2004 U.S. Army Medical Research and Materiel Command, Ad-hoc  1998-1999 Department of Veterans Affairs  1993-present Washington State University Alcohol and Drug Abuse Program	2011	NIH—Ad hoc: NIDA ZDA1 GXM-A; NIDA B/START; ZDA1-JXR-D; ZDA1
ZDA1 GMX-A (2009) ZDA  1999-2005 NIH (NIDA) <b>Standing Member</b> , Medications Development (SEP Chair, 2002)  1999 NIH (NIDA) Medications Development Special Emphasis Panel  1997-2004 U.S. Army Medical Research and Materiel Command, Ad-hoc  1998-1999 Department of Veterans Affairs  1993-present Washington State University Alcohol and Drug Abuse Program		JXR-D – program projects
1999-2005 NIH (NIDA) <b>Standing Member</b> , Medications Development (SEP Chair, 2002) 1999 NIH (NIDA) Medications Development Special Emphasis Panel 1997-2004 U.S. Army Medical Research and Materiel Command, Ad-hoc 1998-1999 Department of Veterans Affairs 1993-present Washington State University Alcohol and Drug Abuse Program	2006-2009	NIH Ad hoc: NIDA-L, ZDA1 RXL-E and NMB (2008), ZDA1 GMX-A and
1999 NIH (NIDA) Medications Development Special Emphasis Panel 1997-2004 U.S. Army Medical Research and Materiel Command, Ad-hoc 1998-1999 Department of Veterans Affairs 1993-present Washington State University Alcohol and Drug Abuse Program		ZDA1 GMX-A (2009) ZDA
1997-2004 U.S. Army Medical Research and Materiel Command, Ad-hoc 1998-1999 Department of Veterans Affairs 1993-present Washington State University Alcohol and Drug Abuse Program	1999-2005	
1998-1999 Department of Veterans Affairs 1993-present Washington State University Alcohol and Drug Abuse Program	1999	` ', ' I I
1993-present Washington State University Alcohol and Drug Abuse Program	1997-2004	
	1998-1999	Department of Veterans Affairs
1997-1998 University of Idaho EPSCoR Foundation	1	•
	1997-1998	University of Idaho EPSCoR Foundation

#### **Editorial Board Member:**

2010-present: Journal of Addiction Research & Therapy

## Ad Hoc Manuscript Reviewer: (approx 12-24 manuscripts/year)

Reviewing Editor for Frontiers in Molecular Neuroscience, Alcoholism Clinical and Experimental Research, Behavioural Brain Research, Biological Psychiatry, BMC Biology; Brain Research, Brain Research Bulletin, Brain Structure and Function, Cell Reports, Drug and Alcohol Dependence, eLIFE, Environmental Health Perspectives, Environmental Research, European Journal of Neuroscience, European Neuropsychopharmacology, Experimental Neurology, Frontiers in Behavioral Neuroscience (and Molecular Neuroscience), Hearing Research, Indian Journal of Medicine, International Journal of Neuropsychopharmacology, International Neuropsychiatric Disease Journal, Journal of Experimental Biology, Journal of Neuroscience, Journal of Psychosomatic Research, Journal of Visualized Experiments, Learning and Memory, Nature Metabolism, Neurobiology of Ageing, Neurobiology of Disease, Neurobiology of Learning and Memory, Neuropsychopharmacology, Neuroscience Letters, Neuroreport, Neuroscience and Biobehavioral Reviews, Neurotoxicology, Proceedings of the National Academy of Sciences; Psychopharmacology, Pharmacology, Biochemistry and Behavior, PLOS One, Radiation Research, Science Advances; Scientific Reports, Toxicology, Translational Psychiatry, Trends in Genetics, Trends in Pharmacological Sciences, Western Journal of Medicine

## **Honors and Awards:**

01/01/87-12/31/88 Traineeship: PHS NRSA (Grant #2 T32 A1 07025-7A1); Immunology

Training Grant.

10/2009 WSU Honor's College Thesis Advisor Award

### **Scientific Organizations:**

Society for Neuroscience

Institute of Translational Health Sciences, University of Washington

College on Problems of Drug Dependence

Sleep Research Society

### Local Groups/Associations

1995-1996	Northern Rocky Mountain Chapter - Society for Neuroscience (Treasurer)
1997-1998	Northern Rocky Mountain Chapter - Society for Neuroscience (President)
2016-present	Society for Neuroscience, Oregon Chapter (secretary, 2020)
2021	Steve Gleason Institute for Neuroscience, WSU Spokane

#### **Service to Legacy Research Institute**

2019-present	Institutional Animal Care and Use Committee
2020	Legacy Research Institute Promotions Committee (Chair)

#### **Service to Oregon Health & Science University**

2020-2021 Program Advisory Committee, Portland Alcohol Research Center

#### Service to Washington State University and Community:

#### **Outreach Presentations and Other Activities:**

- Alcohol and Drug Abuse—presentation to Health and Wellness Center, Fall, 2000
- WSU Mom's Weekend-presentation on Drugs of Abuse, April, 2002
- Alive Sessions: once/year up through 2009
- Biomedical Science Program 5-year review, Marquette University, Spring, 2008
- Established formal partnership with Legacy Research Institute, Portland, OR, 2015
- Presentation to Legislative Staff Tour (Drug Addiction and Memory), WSU-Vancouver, 2015
- WSU-V Neuroscience promotion, STEM Girls Conference, Camus High School 2016, 2017
- Presentation to *Technology Alliance* "Food for Thought" Series at the *Ranier Club* (Drug Addiction and Memory), Seattle, WA, 2016
- Kiggins Theatre "Science on Tap" (Drug Addiction and Memory), Vancouver, WA, 2016
- Washington State House of Representatives presentation to Commerce and Gaming Committee on marijuana research activities at WSU, Olympia, WA, 2016

- Clinton Street Theatre "Science on Tap" (Drug Addiction and Memory), Portland, OR, 2016
- Alberta Rose Theatre "Science on Tap (Drug Addiction and Memory), Portland, OR, 2016
- Portland Humanists Society (Memory of Drug Addiction), Portland, OR, 2017
- Washington State University Advisory Board (Addiction), Vancouver, WA, 2017
- Washington State Legislative and Congressional Staff (Addiction and Stress), Vancouver, WA 2017
- Portland State University (Perineuronal nets and cocaine memories), Portland, OR, 2019

# University Committees at WSU

2003-2004	Alcohol and Drug Abuse Proposal Steering Committee
2003-2014	Alcohol and Drug Abuse Research Program, Director (2003-2014)
2011-2019	Translational Addiction Research Center, Co-director (2011-2019)
2013-2015	Sahlin Award Committee: Research Scholarship & Arts (Chair, 2 years)
2015-2018	Graduate School Mentor Committee
2014-present	Alcohol and Drug Abuse Research Program Advisory Board
2021-2023	Portland Alcohol Research Center, external program advisory committee member

## Department/College Committees at WSU

partment/Cottege Committees at WSO		
1996-1999	Animal Resource Unit Committee (Chair, 1998 & 1999)	
1996-1997	Graduate Student Recruitment Committee (Chair)	
1996-1998	Graduate Studies Committee (VCAPP)	
1996	Space Committee (VCAPP)	
1997-2000	Co-organizer for Brain Awareness activities	
1997	Program Policy Committee (Neuroscience Program)	
1997-2001	Graduate Studies Committee (VCAPP)	
1996-2001	Faculty Mentor, (School of Vet. Med. students)	
1999-2004	Wegner Hall Vivarium Committee	
2002	Neuroscience 5-year Planning Committee (Chair)	
2002-2003	Wegner Hall Vivarium Committee (Chair)	
2002-2003	Neuroscience Curriculum Committee (undergraduateCo-chair)	
2002	Space/Resources Committee	
2002/2003	Search Committee, Wegner Vivarium	
2003-2010	CVM Research Committee (Chair '07 and '08)	
2005	New Faculty Search Committee (Chair)	
2005	Neuroscience Curriculum Committee (undergraduate)	
2005-2007	Pharmacology/Toxicology Admissions Committee	
2006-2007	Graduate Studies Committee	
2007-2010	Chair's Advisory Committee	
2007	VCAPP Planning Committee	
2009/2010	CVM Faculty Executive Committee	

2009/2010	Biomedical Sciences Building Design Committee
2009-present	Neuroscience Program Curriculum Committee
2010	New Faculty Search Committee (Chair)
2011-2016	College of Veterinary Medicine Tenure and Promotion Committee
2012	New Faculty Search Committee (IPN)
2013	New Faculty Search Committee (2 positions, IPN)
2012-2013	5-Year Strategic Planning Committee (IPN)
2012-present	Neuroscience Graduate Program Executive Committee (IPN)
2013-2019	Program Leader, Neuroscience, WSU Vancouver (excluding Fall, 2016)

# Postdoctoral Fellows

1999-2004	Weiran Wu, M.D., Ph.D. – currently Psychiatrist, University Health System, San Antonio, TX
2014-present	Jordan Blacktop, Ph.D. – recipient of NIH K99 award (2018); currently Assistant Professor, Oregon Institute of Technology
2016-2019	John Harkness, Ph.D. – currently CEO of Rewire.com and recipient of NIH SBIR awards (2019, 2021)

# Student Ph.D. Committees

1994	Balakrishna Prasad of Neuroscience (Chair)
1997	Frank Koegler of Neuroscience
1997	Zhiping Cao
1997	Tammy Stobb of Chemistry
1997	Shannon Long of Chemistry
1998	Holly Wayment of Chemistry
1998	Nicole Sanders of Neuroscience
1998	Cynthia Earles of Chemistry
1999	Julie Strattman of Psychology
1999	Jo Anne Alfaro of Chemistry
1999	Eniko Kramer of Psychology
1999	Laura Markowski of Chemistry
2000	Shuang Li (Pharmaceutical Sciences)
2000	Sean Sanders (Neuroscience)
2001	Myung Kim (Chemistry)
2001	Kishor Bugarith (Neuroscience)
2001	Olga Gurkovskaya (Pharmacol/Therap., LSU)
2002	Mike Olsen (Psychology)
2002	Evan Sleipness (Neuroscience) (Co-Chair)
2002	Erin Stoeffel (Psychology)
2003	Starla Meighan (Neuroscience)

2003	Trent Volz (Chemistry)
2003	Nicole Bjorklund (Chemistry)
2006	Pete Meighan (Neuroscience)
2004	Travis Brown (Neuroscience) (Chair)
2005	Sanjib Mukherjee (Neuroscience)
2005	Patrick Elias (Pharmaceutical Sciences)
2007	Adie Wilson (Neuroscience)
2006	Reka Natarajan (Neuroscience)
2006	Fan Liao (Neuroscience)
2006	Caroline Benoist (Neuroscience)
2006	Bhavani Kashyap (U. Idaho, Neuroscience)
2008	Brian Lee (Neuroscience) (Co-chair)
2008	Jenny Browning (Neuroscience) (Co-chair)
2008	Veronica Chiu (Chemistry)
2010	Seth Davis (Psychology)
2011	Brad Winters (Neuroscience)
2010	Peter Neumann (Neuroscience) (Co-chair until 2012)
2012	Megan Slaker (Neuroscience) (Chair)
2012	Melissa Mehalick (Psychology-WSU Vancouver)
2013	Phillip Uribe (Neuroscience-WSU Vancouver)
2014	Matthew Lambert (School of Biological Sciences-WSU Vancouver)
2014	Jessica Higginbotham (Neuroscience-WSU Pullman)
2014	Christie Pizzimenti (Behavioral Neuroscience, OHSU)
2015	Ram Kandasamy (Neuroscience-WSU Vancouver)
2015**	Jeff Hoyt (Neuroscience-WSU Vancouver)
2016	Rikki Quinn (University of Newcastle, Australia; final PhD thesis only)
2017	Maria Carbó Gas (Universitat Jaume I, Spain; final PhD thesis only)
2017	Priyanka Bushana (WSU Spokane) (Co-chair)
2017	Pique Choi (Neuroscience, WSU Pullman)
2018** ** Current	Angela Gonzalez (Neuroscience, WSU Vancouver (Chair)
Ourient	
Student M.S.	S. Committees
1996	Ken Bell of Neuroscience
1997	Jeff Stobb of Neuroscience
1998	Susan Bale of Zoology
1999	Mitch Green of Chemistry
2000	Cortney Wright (Chemistry)
2000	Christopher Sanchez (Neuroscience, Chair)
2000	Rick Schumacher (Chemistry)
2000	Shannon George (Chemistry)

	2004	Kathleen Carter (Neuroscience) (Chair)
	2004	Davelle Cocking (Pharmaceutical Sciences, Chair)
	2005	Rick Heckert (Pharmaceutical Sciences)
	2008	Karen Gerde (Psychology)
	2012	Derrick Phillips (Neuroscience)
Gr		udent Rotations
	1999	Lichao Chen (Neuroscience)
	2000	Shuang Li (Pharmaceutical Sciences)
	2000	Christopher Sanchez (Neuroscience)
	2000	Jeff Herman (Pharmaceutical Sciences)
	2000	Theresa Bjorness (Neuroscience)
	2002	Evan Sleipness (Neuroscience)
	2003	Travis Brown (Neuroscience)
	2003	Kathleen Carter
	2004	Davelle Cocking (Pharm. Sci.)
	2005	Karina Villa (Pharm. Sci.)
	2006	Robert Olson (Neuroscience)
	2007	Adie Wilson (Neuroscience)
	2008	Jenny Browning (Neuroscience)
	2008	Brian Lee (Neuroscience)
	2008	Stella Feng (Pharm. Sci.)
	2009	Peter Neumann (Neuroscience)
	2010	Rong Guo (Neuroscience)
	2011	Kimberly Honn (Neuroscience)
	2011	Megan Slaker (Neuroscience)
	2017	Vanessa Real (Neuroscience)
	2017	Isis Gil Miravet (visiting PhD student from Universitat Jaume I, Spain for 4 mo)
Пи	deraradu	ate 495/499 Students
07.	2001-200	
	2001-200	•
	2002-200	
	2003	Anastacia Shaver
	2003-200	
	2003 200	Patrick Hines
	2004-200	
	2005-200	
	2005-200	
	2006-200	

2008	*Colin Kennedy (WSU Alcohol and Drug Abuse Program award)
2008-2011	*Katie Wyrick (WSU Alcohol and Drug Abuse Program award
2009-2011	*Tom Bennett (WSU Alcohol and Drug Abuse Program award)
2009-2010	*Sam Kammerzell
2009-2010	Nick Sparks
2009-2011	Laura Curtis
2010-2012	Christopher Cao
2010-2012	Erik Larson
2010-2011	Wesley Millard
2010-2011	Ellen Shriner
2011-2013	*Cynthia Jewett (WSU Pullman)
2012-2014	*Ben Heckler (Portland State University)
2013-2014	Joel Ohrt (WSU Vancouver; WSU Alcohol and Drug Abuse Program award)
2013-2014	Jesse Chiem (University of Portland)
2013-2014	Silas Aho (WSU Vancouver)
2013-2017	*Priya Kudva (WSU Vancouver)
2013-2014	Ellie Ficco (WSU Vancouver)
2013-2014	Kyle Campion (WSU Vancouver)
2014-2016	*Kyrie Reyes (WSU Vancouver; WSU Alcohol and Drug Abuse Program award)
2014-2016	Kelsey O'Neill (WSU Vancouver)
2014-2017	Nathan Allen (WSU Vancouver)
2015-2018	*Angela Gonzalez (WSU Vancouver) - now Graduate Student in the lab
2016-2016	David Choi (WSU Vancouver)
2016-2018	*Jereme Wingert (WSU Vancouver; WSU Alcohol and Drug Abuse Program award) post-bacc in the lab until Fall 2021
2017-2018	Holly D'Andrea (WSU Vancouver)
2018-2020	Ashlynn Dean (WSU Vancouver)
2018-2020	Jonathan Anguiano (WSU Vancouver)
2018-2020	Abigail Gligor (WSU Vancouver)
2019-2020	Blake Marble (WSU Vancouver)
2019-2021	Jordan Kronstad (WSU Vancouver)
2021-2022	Tenzin Nordon (WSU Vancouver)
2021-2022	Roman Cimkovich (Portland State University)
+2022-	Brittani Wallsten (Portland State University)
+2023-	Jacqueline Minder-Almanza (WSU Vancouver)

<sup>+</sup> Current students

High School Students
2015 Nicole Lobokov (Camus High School summer project)

<sup>\*</sup> Co-authors on peer-reviewed publication

2016-2018	Monica Chen (Camus High School; winner of 2017 OregonBio Research Fast Pitch event at OMSI, Portland, OR)
Honor's Thesis	Advisor
2001-2003	Elizabeth Ferluga (graduated with distinction)
2003-2004	Ryan Barnes
2003-2004	Amanda Lamp
2008-2009	Colin Kennedy
2009-2010	Sam Kammerzell (graduated with distinction)
2009-2011	Laura Curtis
2013-2015	Ellie Ficco (WSU Vancouver)
2014-2016	Kelsey O'Neill (WSU Vancouver)
TEACHING (c	contact hours listed)
Graduate	
Neuro 520:	Functional Neuroscience (≈ 8 students) 25 hr (Fall, 2001) 17 hr (Fall, 2002)
Neuro 540:	Neuropharmacology (≈ 10 students) 3 hr (Spring 1995) 6 hr (Spring 1997)
Neuro 540:	Special Topics in Neuroscience (5-8 students) 10 hr (Spring 2003Course Director) 15 hr (Spring 2008Course Director) 6 hr (Fall 2010) 3 hr (Fall 2012) 1 hr (Fall 2013)
<b>Neuro 592:</b>	Research Writing and Seminar (2-9 students) Meets once/week, 3 hr class time + individual time with students Course Director (Spring, 2007—2018, excluding Fall 2016)
Pharm/Tox	502: Faculty Research in Pharmacology/Toxicology (≈ 6 students) 1 hr (Fall, 2002) 1 hr (Fall, 2003) 1 hr (Fall, 2005)
Pharm/Tox	506: Principles of Pharmacology (Fall 1999) 4 hr
Psych 579:	Stress and Behavior (≈ 10 students) 2 hr (Spring 1995)
VPh/PT 529	9: Cellular/Molecular Neurobiology (≈ 10 students) 4 hr (Spring 1995) 6 hr (Spring 1996) 3 hr (Spring 1997)

**NURS 563** 

```
24 hr (Spring 1999)
                 20 hr (Spring 2000)
                  15 hr (Spring 2001)
                 24 hr (Spring 2004)
                 20 hr (Spring 2005--Course Director)
                  20 hr (Spring 2006--Course Director)
                  20 hr (Spring 2007--Course Director)
                 8 hr (Spring 2008--Course Director)
                 8 hr (Spring 2009--Course Director)
   VPh 555: Cell Physiology (≈ 15 students)
                 5 hr (Fall, 2000)
                 5 hr (Fall, 2001)
                 5 hr (Fall, 2002)
   VPh 590: VCAPP Seminar Series
                Course director (Fall 2000 and Spring 2001)
                Course director (Spring 2003)
      One lecture on Addiction (Spring 2013)
   Ed Psych 502: Educational Psych (17 students)
                One lecture on Memory and the Brain (Fall 2015)
Undergraduate
   Neuro 138: Special Topics in Neuroscience (≈ 16-27 students)
                Meets once/week for 1 hr
                 2 hr (Fall, 1999)
                 2 hr (Spring, 2000)
                  1 hr (Fall, 2002 – 2010)
                  Approx. 1/3-1/2 of course organizer (Spring 2014)
                  Course director since Spring 2015
    Biology 210:
                     One lecture on drugs of abuse
    Neuro 303: Neurochemistry (undergraduate core course- 3 credit course) (≈ 10 students)
                 40 hr (Spring, 1998--Course Director)
                 28 hr (Spring, 1999--Course Director)
   Neuro 403: Cellular Neurobiology (≈ 17-35 students)
                 30 hr (Spring, 2001--Course Director)
                 27 hr (Fall, 2001--Course Director)
                 27 hr (Fall, 2002--Course Director)
                 45 hr (Fall, 2003--Course Director)
```

35 hr (Fall, 2004--Course Director) 30 hr (Fall, 2005--Course Director) 24 hr (Fall, 2006--Course Director) 15 hr (Fall, 2007-2012--Course Director)

15 hr (Spring, 2013, 2015)

15 hr (Fall, 2017, 2018) 1 hr (Fall, 2021, 2022)